News
The poster will highlight interim efficacy and safety data on MT-6402, MTEM’s ETB program designed to activate T-cells through direct cell-kill of immunosuppressive PD-L1+ immune cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback